T-Cell Immunotherapy Pipeline to Witness Many Collaborations in the Coming Years

The T-cell immunotherapy exhibits strong pipeline with estimated 139 drug candidates in 2016.

September 6, 2017 /MarketersMedia/ —

The study analyzed that the T-cell immunotherapy pipeline comprised of 139 therapeutic candidates in different stages of development. The high prevalence of cancer across the globe fuels the extensive research and development for the T-cell immunotherapeutic. T-cell immunotherapy is emerging as novel and promising approach for the treatment of cancer. It is gaining huge traction globally, for its several advantages over conventional therapies such as very low or no side effects and high specificity.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/t-cell-immunotherapy-pipeline-analysis/report-sample

CAR T-cells are the modified T-cells used to express CARs, which recognize specific antigens present on targeted cell. CARs are specifically designed synthetic receptors, linked with the single-chain variable fragment (scFV) of a monoclonal antibody. The domain includes T-cell receptor CD3-zeta chain, which graft specificity into an immune effector cell. It mediates T-cell cytotoxicity and activation when bound to a target cell.

Pre-Purchase Enquiry at: https://www.psmarketresearch.com/send-enquiry?enquiry-url=t-cell-immunotherapy-pipeline-analysis

Some of the key players developing T-cell immunotherapies are Novartis AG, Cellular Biomedicine Group, Inc., Kite Pharmaceuticals Inc. and others.

Contact Info:
Name: Abhishek
Email: enquiry@psmarketresearch.com
Organization: P&S Market Research
Address: 347, 5th Ave. #1402, New York City, NY – 10016
Phone: +1-888-778-7886

Source URL: https://marketersmedia.com/t-cell-immunotherapy-pipeline-to-witness-many-collaborations-in-the-coming-years/236785

For more information, please visit https://www.psmarketresearch.com/market-analysis/t-cell-immunotherapy-pipeline-analysis

Source: MarketersMedia

Release ID: 236785